A Phase IIIb Study of BMS-188667 in Subjects With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate
Status:
Completed
Trial end date:
2010-05-01
Target enrollment:
Participant gender:
Summary
The only trial in participants who are methotrexate-inadequate responders and have active
Rheumatoid Arthritis, in which gadolinium-enhanced Magnetic Resonance Imaging; Bone Mineral
Density; and biochemical markers of bone, cartilage, and synovial tissue metabolism are used
to evaluate early effects (4 months) of Abatacept on inflammation/structural damage. Study
will provide valuable mechanism-of-action information on how Abatacept exerts its effects
(including on bone) through new techniques.